Senores Pharma's subsidiary Havix completes USFDA inspection with 3 observations
The USFDA issued three Form 483 observations following the inspection. According to the company, all the observations are procedural and minor in nature. Havix is committed to addressing the points raised and will submit its response to the USFDA within the stipulated 15-day period.
In the exchnge filings, the company shared, 'We hereby inform that Havix Group Inc. D/B/A Aavis Pharmaceuticals ('Havix'), a Material Subsidiary of the Company situated at 9488 Jackson Trail Road, Hoschton, Georgia 30548, USA has completed the United States Food & Drug Administration ('USFDA') inspection of its manufacturing facility from July 21, 2025 to July 25, 2025 with 3 (Three), 483 observations.'
This development reaffirms Senores Pharma's ongoing commitment to maintaining global quality standards at its facilities.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Alkem Laboratories Q1 Results: Revenue jumps 11.2% YoY to Rs 3,371 crore, net profit up Rs 21.45% YoY
By Aman Shukla Published on August 12, 2025, 13:40 IST Alkem Laboratories has delivered a strong set of numbers for the first quarter of FY26, with growth across revenue, profit, and operational performance. The company reported a consolidated net profit of ₹668 crore, marking a solid 21.45% year-on-year jump from ₹550 crore in the same quarter last year. Revenue also saw healthy growth, rising 11.2% to ₹3,371 crore compared to ₹3,031.8 crore a year ago. The pharmaceutical major's EBITDA stood at ₹739 crore, up 21.35% from ₹609 crore, with margins improving to 21.9% from 20% in the previous year. The domestic business remained the key growth driver, clocking sales of ₹2,265 crore, a 12% increase from the previous year, contributing 68.3% to total sales. According to IQVIA (SSA) data, the company outperformed the Indian Pharmaceutical Market (IPM) in seven therapies, including Gastrointestinal, Vitamins/Minerals/Nutrients, Pain Management, Anti-Diabetics, Neuro/CNS, Respiratory, and Dermatology, with growth ranging from 1.1x to 2.3x the market rate. On the international front, sales stood at ₹1,053.9 crore, registering an 8.9% year-on-year rise. The US business contributed ₹698.2 crore, up 8.8% from last year and accounting for 21% of total sales. Non-US international markets generated ₹355.6 crore, up 9.1%, contributing 10.7% to total revenue. In the US market, Alkem filed its first Biologics License Application (BLA), received five ANDA approvals (including two tentative), and launched three new products during the quarter. As of June 30, 2025, the company had filed 185 ANDAs, two NDAs, and one BLA with the USFDA, receiving approvals for 160 ANDAs (including 15 tentative) and both NDAs. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
2 hours ago
- Business Upturn
Gland Pharma gets USFDA approval for Cangrelor injection with 180-day exclusivity
Gland Pharma Limited, a leading player in the generic injectable and ophthalmic pharmaceutical space, has received the green light from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Cangrelor for Injection, 50 mg/vial. The approved product is bioequivalent and therapeutically equivalent to the reference listed drug KENGREAL, developed by Chiesi USA Inc. Cangrelor Injection is prescribed as an adjunct to percutaneous coronary intervention (PCI) to lower the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not received a P2Y12 platelet inhibitor and are not being administered a glycoprotein IIb/IIIa inhibitor. One major highlight of this approval is that Gland Pharma will enjoy 180 days of generic drug exclusivity in the U.S. market — a key competitive advantage that could boost its revenue in the near term. According to IQVIA data, Cangrelor Injection recorded approximately USD 122 million in U.S. sales in the 12 months ending June 2025, highlighting the strong market potential for Gland Pharma's launch. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
3 hours ago
- Business Upturn
Air Astana partners with RateGain to boost pricing agility with AI-powered airfare intelligence
RateGain Travel Technologies Limited, a global leader in AI-powered SaaS solutions for the travel and hospitality industry, has announced a strategic partnership with Air Astana JSC, the largest airline group in Central Asia and the Caucasus regions. Air Astana, alongside its subsidiary FlyArystan, has selected RateGain's cutting-edge platform, AirGain, to enhance its airfare pricing strategy with real-time competitive insights. As Air Astana continues to expand its international and regional network connecting Kazakhstan to Europe, Asia, and the Middle East, the airline faces an increasingly complex pricing environment. The collaboration with RateGain's AirGain platform equips Air Astana's pricing and revenue management teams with accurate, real-time data. This enables faster, more confident decision-making, allowing the airline to respond swiftly to market fluctuations while safeguarding revenue and maintaining a strong competitive edge. Known for its operational excellence and modern fleet, Air Astana has consistently been recognized for its award-winning service. The airline recently clinched the title of 'Best Airline in Central Asia and CIS' for the 14th consecutive year at the 2025 Skytrax Awards. This partnership further solidifies Air Astana's commitment to adopting innovative technology solutions that drive efficiency and growth across its commercial operations. Unlike traditional fare tracking tools, AirGain offers Air Astana real-time visibility into competitor pricing across multiple channels, including airline websites, online travel agencies (OTAs), and global distribution systems (GDSs). This empowers the airline to monitor market trends, detect anomalies, benchmark fares, and react quickly to shifting market dynamics. By leveraging RateGain's AI-powered airfare pricing intelligence, Air Astana aims to enhance pricing agility, improve revenue management, and sustain its leadership position in the competitive aviation landscape of Central Asia and beyond. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
